Specific concerns for Crohn's patients include: Nausea and vomiting : May exacerbate existing symptoms or lead to dehydration, particularly concerning in patients with active disease Diarrhea : Difficult to differentiate from Crohn's-related diarrhea, potentially delaying recognition of disease flares Abdominal pain : May mask or mimic Crohn's-related pain, complicating clinical assessment Reduced oral intake : Appetite suppression combined with nausea may worsen nutritional deficiencies common in IBD Additional FDA-labeled risks include: Acute gallbladder disease : Cholelithiasis and cholecystitis occur more frequently with semaglutide, particularly with rapid weight loss [12] [15] Acute kidney injury : Dehydration from gastrointestinal side effects may lead to kidney injury Pancreatitis : Patients should be monitored for severe, persistent abdominal pain, sometimes radiating to the back Rare but serious gastrointestinal adverse events reported in post-marketing surveillance include cases of bowel obstruction and ileus
Protein is particularly important
What changes is the speed of weight loss, not the way the medicine works
In February 2025, the FDA declared the U.S
There is no FDA guidance supporting routine every-other-week dosing as a maintenance strategy
When it comes to weight loss, no two journeys are the same
